Bone Support

Share Price

  • Contact Us
Follow
  • US site
    • Global English Site
    • US site
    • Global Swedish Site
  • Bonesupport
    • Message from the CEO
    • Vision & Mission
    • Sustainability
    • History
    • Management
    • The Board
    • Our Partners
    • Careers
  • Products
    • CERAMENT® G with Gentamicin
    • CERAMENT® BONE VOID FILLER
    • Delivery Devices for CERAMENT®
  • Innovation
    • Pipeline
    • CERTiFy Clinical Trial
  • Medical Professionals
    • TRAUMA: WHY USE CERAMENT®
    • BENIGN BONE TUMORS: WHY USE CERAMENT®
    • REVISION ARTHROPLASTY: WHY USE CERAMENT®
    • FOOT AND ANKLE: WHY USE CERAMENT®
    • CERAMENT® G Reimbursement
  • Investors
    • Financials
    • Financial Reports
    • Presentations
    • The Share
    • Shareholders
    • Analyst Coverage
    • Corporate Governance
    • Calendar
    • Q&A
    • Definitions
  • Patients
    • Bone Grafts
    • BONE DEFECTS CAUSED BY TRAUMA
    • BONE DEFECTS CAUSED BY BENIGN BONE TUMORS
    • BONE DEFECTS CAUSED BY HIP AND KNEE REVISIONS
  • Events
  • Media
    • Press Releases
    • Publications and Resources
    • Multimedia
  • Contact Us
  • Global English Site
  • US site
  • Global Swedish Site

  • Delivery Devices for CERAMENT®

  • CERAMENT® G Reimbursement

  • CAPITAL MARKETS DAY 2022

  • Delays within FDA postpones CERAMENT G De Novo decision

  • BONESUPPORT Holding AB (publ) – Publishes full year report 2021

  • BONESUPPORT HOLDING AB (publ) – Invitation to conference call and webcast for year end report 2021

  • Change in number of shares and votes in BONESUPPORT Holding AB (publ)

  • BONESUPPORT signs distribution agreement with OrthoPediatrics

  • Change in number of shares and votes in BONESUPPORT Holding AB (publ)

  • Change in number of shares and votes in BONESUPPORT Holding AB (publ)

1 2 3 … 24 »

©BONESUPPORT AB 2023. ALL RIGHTS RESERVED. CERAMENT and BONESUPPORT are registered Trademarks of BONESUPPORT AB.

  • Home
  • Contact Us
  • Privacy Policy
  • Cookie Policy